Prima BioMed Announces Quarterly Activity Report for Quarter ending 31 March 2012
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwire) -- 04/27/12 -- Prima BioMed (Prima) (ASX: PRR) (NASDAQ: PBMD) today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2012.
The cash balance as of 31 March 2012 was A$ 42.8 million. The majority of funds spent during the quarter are related to development activities of Prima's lead product Cvac™.
Business highlights from the quarter:
TGA grants Manufacturing License for CVac™ in Australia
Commencement of ovarian cancer patient enrolment for CANVAS
Registration Statement filed for NASDAQ listing
Japanese patent granted for Cripto-1 antibody
For more details about these highlights, please refer to Prima's previous releases on the ASX website.
Introduced 31/3/2000. Amended 30/9/2001
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
3.2 $12 million equity drawdown facility in place with Foretrend Securities Pty Ltd.
1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
2. This statement does give a true and fair view of the matters disclosed.
Sign Here:
Date: Friday 27th April 2012
Company Secretary
Print Name: Ian Bangs
1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.
6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
9.2 - itemised disclosure relating to acquisitions
9.4 - itemised disclosure relating to disposals
12.1(a) - policy for classification of cash items
12.3 - disclosure of restrictions on use of cash
13.1 - comparative information
3. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.
Level 7, 151 Macquarie Street, Sydney 2000
Ph: +61 (0) 2 9276 1224
Fax: +61 (0) 2 9276 1284
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2012 - 07:15 Uhr
Sprache: Deutsch
News-ID 1108066
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SYDNEY, AUSTRALIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 119 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Announces Quarterly Activity Report for Quarter ending 31 March 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
